

Research and Development  
Pointer Court  
Royal Lancaster Infirmary  
Ashton Road  
Lancaster  
LA1 4RP

## COVID-19 Vaccine Study

We are writing to you to see if you would be interested in participating in a clinical research study of an experimental vaccine against the SARS-CoV-2 virus. As you are probably aware, this virus has caused a global outbreak of an illness called coronavirus disease-19 (called “COVID-19”) around the world.

In COVID-19, patients have flu-like symptoms such as fever, coughing, sore throat, fatigue, nasal discharge and shortness of breath. Serious cases of COVID-19 can progress to pneumonia (infection of the lungs) and death.

So far, there are no approved vaccines available to prevent or protect against SARS-CoV-2.

Novavax, Inc. (Sponsor) is developing a vaccine that aims to prevent this virus from infecting people and/or preventing serious illness if infection occurs.

About 9000 males and females between the ages of 18 and 84 years with and without the presence of additional medical problems will take part in this study in the UK.

If it is determined that you are eligible to participate in the study, the study vaccination will be given on Day 0 and Day 21. You will then attend the study site for follow up visits on Day 35 (14 days after second study vaccination) and at 3,6 and 12 months after last study vaccination. All visits will involve only day visits to the study site. You may have to attend unscheduled (extra) visits if you develop COVID-19 symptoms to see if you have COVID-19 disease.

To find out more about this research study and learn if you may be eligible to participate, please call 01524 512134 and ask for a member of the research team.

Thank you for your consideration. We hope to hear from you soon.

Yours sincerely,

Dr Andrew Higham,  
Principal Investigator